Tyrosine Phosphorylation of Grb2: Role in Prolactin/Epidermal Growth Factor Cross Talk in Mammary Epithelial Cell Growth and Differentiation

ABSTRACT Characterizing mechanisms regulating mammary cell growth and differentiation is vital, as they may contribute to breast carcinogenesis. Here, we examine a cross talk mechanism(s) downstream of prolactin (PRL), a primary differentiation hormone, and epidermal growth factor (EGF), an important proliferative factor, in mammary epithelial cell growth and differentiation. Our data indicate that EGF exerts inhibitory effects on PRL-induced cellular differentiation by interfering with Stat5a-mediated gene expression independent of the PRL-proximal signaling cascade. Additionally, our data show that PRL is a potent inhibitor of EGF-induced cell proliferation. We identify tyrosine phosphorylation of the growth factor receptor-bound protein 2 (Grb2) as a critical mechanism by which PRL antagonizes EGF-induced cell proliferation by attenuating the activation of the Ras/mitogen-activated protein kinase (MAPK) pathway. Together, our results define a novel negative cross-regulation between PRL and EGF involving the Jak2/Stat5a and Ras/MAPK pathways through tyrosine phosphorylation of Grb2.

[1]  T. Burke,et al.  Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. , 2006, Anti-cancer drugs.

[2]  J. Xie,et al.  Signal transducer and activator of transcription-5 activation and breast cancer prognosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. Muller,et al.  The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. , 1999, Experimental cell research.

[4]  L. Schuler,et al.  Prolactin induces ERα-positive and ERα-negative mammary cancer in transgenic mice , 2003, Oncogene.

[5]  L. Hennighausen,et al.  Stat5a is mandatory for adult mammary gland development and lactogenesis. , 1997, Genes & development.

[6]  Serge Lemay,et al.  The p38 MAPK Pathway Is Required for Cell Growth Inhibition of Human Breast Cancer Cells in Response to Activin* , 2001, The Journal of Biological Chemistry.

[7]  J. Lebrun,et al.  Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. , 2006, Cancer research.

[8]  D. Taverna,et al.  Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells. , 1995, Molecular endocrinology.

[9]  S. Ali,et al.  Prolactin Receptor Regulates Stat5 Tyrosine Phosphorylation and Nuclear Translocation by Two Separate Pathways* , 1998, The Journal of Biological Chemistry.

[10]  A. Ullrich,et al.  The adaptor function of SHP-2 downstream of the prolactin receptor is required for the recruitment of p29, a substrate of SHP-2. , 2003, Cellular signalling.

[11]  B. Groner,et al.  Prolactin regulation of beta‐casein gene expression and of a cytosolic 120‐kd protein in a cloned mouse mammary epithelial cell line. , 1988, The EMBO journal.

[12]  N. Horseman,et al.  Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene , 1997, The EMBO journal.

[13]  David C. Lee,et al.  Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. , 1999, Development.

[14]  A. Sultan,et al.  Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells , 2005, Oncogene.

[15]  C. Clevenger.  Role of prolactin/prolactin receptor signaling in human breast cancer. , 2003, Breast disease.

[16]  K. Henkels,et al.  Short-hairpin RNA-mediated stable silencing of Grb2 impairs cell growth and DNA synthesis. , 2007, Biochemical and biophysical research communications.

[17]  A. Ullrich,et al.  A single phosphotyrosine residue of the prolactin receptor is responsible for activation of gene transcription. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. V. van Etten,et al.  Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling , 2001, The EMBO journal.

[19]  N. Horseman,et al.  Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth , 2000, Oncogene.

[20]  P. Kelly,et al.  Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. , 1997, Genes & development.

[21]  F G Robertson,et al.  Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions , 2007, Oncogene.

[22]  Y. Yarden.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[23]  J. Black,et al.  Prolactin and epidermal growth factor regulation of the proliferation, morphogenesis, and functional differentiation of normal rat mammary epithelial cells in three dimensional primary culture , 1995, Journal of cellular physiology.

[24]  Dajun Yang,et al.  Potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics. , 2003, Bioorganic & medicinal chemistry letters.

[25]  P. Kelly,et al.  Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma. , 2006, The Journal of endocrinology.

[26]  S. Fenton,et al.  Prolactin inhibits EGF-induced DNA synthesis in mammary epithelium via early signaling mechanisms: possible involvement of protein kinase C. , 1997, Experimental cell research.

[27]  H. Rui,et al.  Impaired Alveologenesis and Maintenance of Secretory Mammary Epithelial Cells in Jak2 Conditional Knockout Mice , 2004, Molecular and Cellular Biology.

[28]  B. Mayer,et al.  Dominant-negative mutants of the SH2/SH3 adapters Nck and Grb2 inhibit MAP kinase activation and mesoderm-specific gene induction by eFGF in Xenopus , 1998, Oncogene.

[29]  A. Ullrich,et al.  The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling , 1992, Cell.

[30]  Sheila M. Thomas,et al.  Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases , 1992, Nature.

[31]  H. Lane,et al.  ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.

[32]  L. Schuler,et al.  Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells. , 2004, Molecular endocrinology.

[33]  H. Yamashita,et al.  Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. , 2006, Endocrine-related cancer.

[34]  Xin Li,et al.  Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells , 2006, Oncogene.

[35]  Lothar Hennighausen,et al.  Information networks in the mammary gland , 2005, Nature Reviews Molecular Cell Biology.

[36]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[37]  L. Schuler,et al.  Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. , 2003, Oncogene.

[38]  J. Blenis,et al.  Signal transduction via the MAP kinases: proceed at your own RSK. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Victor J. Quijano,et al.  Prolactin Decreases Epidermal Growth Factor Receptor Kinase Activity via a Phosphorylation-dependent Mechanism* , 1998, The Journal of Biological Chemistry.